Matthew Judson is a research associate in the UNC Neuroscience Center at the University of North Carolina at Chapel Hill.
Matthew Judson
Research associate
University of North Carolina at Chapel Hill
From this contributor
Angelman syndrome: Bellwether for genetic therapy in autism
It is not a matter of whether there will be clinical trials of genetic therapy for Angelman syndrome, but when.
Angelman syndrome: Bellwether for genetic therapy in autism
Insights for autism from Angelman syndrome
Deletions or duplications of the UBE3A gene lead to both Angelman syndrome and some cases of autism, respectively. Studying the effects of altered gene dosage in this region will provide insights into brain defects and suggest targets for therapies for both disorders, says expert Benjamin Philpot.
Insights for autism from Angelman syndrome
Explore more from The Transmitter
Exon-skipping approach boosts levels of key Rett syndrome protein
Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.
Exon-skipping approach boosts levels of key Rett syndrome protein
Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.
Frameshift: How Caitlin Vander Weele made science communication her business
Her favorite part of research was talking about it. So she left academia and turned that passion into a successful company.
Frameshift: How Caitlin Vander Weele made science communication her business
Her favorite part of research was talking about it. So she left academia and turned that passion into a successful company.
Signs of aging vary across brain cells
Senescence presents differently depending on the cell type, toxic trigger and neighboring cells, two new studies find.
Signs of aging vary across brain cells
Senescence presents differently depending on the cell type, toxic trigger and neighboring cells, two new studies find.